Ironwood Pharmaceuticals/$IRWD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ticker
$IRWD
Sector
Primary listing
Employees
100
Headquarters
Website
IRWD Metrics
BasicAdvanced
$678m
6.68
$0.62
0.30
-
Price and volume
Market cap
$678m
Beta
0.3
52-week high
$5.78
52-week low
$0.67
Average daily volume
2.4m
Financial strength
Current ratio
1.406
Quick ratio
1.381
Long term debt to equity
-181.554
Total debt to equity
-275.097
Interest coverage (TTM)
5.97%
Profitability
EBITDA (TTM)
203.842
Gross margin (TTM)
75.20%
Net profit margin (TTM)
28.26%
Operating margin (TTM)
55.89%
Effective tax rate (TTM)
40.41%
Revenue per employee (TTM)
$3,620,000
Management effectiveness
Return on assets (TTM)
33.15%
Return on equity (TTM)
-37.07%
Valuation
Price to earnings (TTM)
6.675
Price to revenue (TTM)
1.851
Price to book
-3.12
Price to tangible book (TTM)
-3.1
Price to free cash flow (TTM)
5.965
Free cash flow yield (TTM)
16.76%
Free cash flow per share (TTM)
0.691
Growth
Revenue change (TTM)
13.80%
Earnings per share change (TTM)
-405.14%
3-year revenue growth (CAGR)
-4.66%
10-year revenue growth (CAGR)
6.83%
3-year earnings per share growth (CAGR)
-14.99%
10-year earnings per share growth (CAGR)
-3.26%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Business Wire·1 month ago
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat·2 months ago
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs